ABSTRACT
Propósito: Evaluar la eficacia de la inyección intravítrea de bevacizumab en pacientes diagnosticados de coriorretinopatía serosa central crónica. Método: Estudio de ocho pacientes con corioretinopatía serosa central tratada con inyección intravitrea de bevacizumab. Se incluye la agudeza visual con la escala de Snellen y el grosor de la mácula, ambas pre- y post-inyección. Resultados: La edad media de los pacientes fue de 50,25 años. El estudio se evaluó al cabo de un mes de evolución. La agudeza visual previa media fue de 0,431±0,249 líneas de visión y la posterior a la inyección fue de 0,631±0,310 líneas de visión (P=0,017). El grosor medio de la mácula fue de 351,25±78,492 μm y post-tratamiento de 183,50±22,640 μm (P=0,012).Conclusión: El bevacizumab intravítreo puede ser una alternativa en los pacientes con coriorretinopatía serosa central ya que existe una mejoría objetiva tanto de la agudeza visual como del grosor macular objetivado con tomografía de coherencia óptica(AU)
Purpose: To evaluate the efficacy of intavitreal injection of bevacizumab in patients with chronic central serous chorioretinopathy. Methods: A study of 8 patients with central serous chorioretinopathy who were treated with intravitreal injection of bevacizumab. We studied the visual acuity with Snellenis method and the foveal thickness, before and after the injection. Results: The mean age of the patients was 50.25 years. After one month of follow-up, visual acuity before the injection was 0.431±0.249 vision lines and after was 0.631±0.310 vision lines (P=.017).The foveal thickness was 351.25±78.492μm and after treatment was 183.50±22.640μm (P=.012). Conclusions: Intravitreal bevacizumab can be an alternative treatment in patients with serous central chorioretinopathy as it leads to a better objective visual acuity and foveal thickness with optical coherence tomography(AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Central Serous Chorioretinopathy/drug therapy , Intravitreal Injections/instrumentation , Intravitreal Injections/methods , Evaluation of the Efficacy-Effectiveness of Interventions , Visual Acuity , Tomography, Optical Coherence/methods , Ofloxacin/therapeutic use , Light Coagulation/methods , Light Coagulation/trends , Antibodies, Monoclonal/therapeutic use , Central Serous Chorioretinopathy/diagnosis , Treatment Outcome , Tomography, Optical Coherence/instrumentation , Central Serous Chorioretinopathy/physiopathology , Intravitreal Injections/trends , Intravitreal Injections , Tomography, Optical Coherence/trends , Tomography, Optical Coherence , Angiography/trends , AngiographyABSTRACT
PURPOSE: To evaluate the efficacy of intavitreal injection of bevacizumab in patients with chronic central serous chorioretinopathy. METHODS: A study of 8 patients with central serous chorioretinopathy who were treated with intravitreal injection of bevacizumab. We studied the visual acuity with Snellens method and the foveal thickness, before and after the injection. RESULTS: The mean age of the patients was 50.25 years. After one month of follow-up, visual acuity before the injection was 0.431 ± 0.249 vision lines and after was 0.631 ± 0.310 vision lines (P=.017).The foveal thickness was 351.25 ± 78.492 µm and after treatment was 183.50 ± 22.640 µm (P=.012). CONCLUSIONS: Intravitreal bevacizumab can be an alternative treatment in patients with serous central chorioretinopathy as it leads to a better objective visual acuity and foveal thickness with optical coherence tomography.
